Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs [Commentary]

E. DAY ; T. BRODER ; J. BRUNEAU ; S. CRUSE ; M. DICKIE ; S. FISH ; C. GRILLON ; N. LUHMANN ; K. MASON ; E. MCLEAN ; S. TROOSKIN ; C. TRELOAR ; J. GREBELY | 2019
Dans International Journal of Drug Policy (Vol.66, April 2019) Article : Périodique

It is estimated that 6.1 million people with recent injecting drug use (PWID) are living with hepatitis C virus (HCV). Although HCV-related morbidity and mortality among PWID continues to increase, the advent of direct acting antiviral (DAA) HCV[...]

Plus d'info

Ajouter à la sélection